The use of lipid-lowering drug therapy in children and adolescents

Current Opinion in Investigational Drugs

Volumn 10, Issue 3, 2009, Pages 224-231

  Avis, H J ^a   Vissers, M N ^a   Wijburg, F A ^a   Kastelein, J J P ^a   Hutten, B A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Atherosclerosis; Children; Dyslipidemia; Lipid; Prevention

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; COLESEVELAM; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL DISCOMFORT; AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHILD CARE; CHILDHOOD; CHOLESTEROL METABOLISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIFESTYLE MODIFICATION; LIVER DISEASE; LONG TERM CARE; MUSCLE DISEASE; MYOPATHY; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; BILE ACIDS AND SALTS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; CLOFIBRIC ACID; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ION EXCHANGE RESINS; NIACIN; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 62249086456     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Global Burden of Disease 2004. WHO, Geneva, Switzerland(2008). www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-part2. pdf
2. Kube, N, Ssolowjew A: Über die lipoidablaserung in der aorta von kindern im frühen säuglingsalter. Frankfurt Ztschr f Path (1930) 40:302-306.
3. Duff GL, McMillan GC: Pathology of atherosclerosis. Am J Med (1951) 11(1):92-108.
4. Enos WF, Holmes RH, Beyer J: Coronary disease among United States soldiers killed in action in Korea; preliminary report. J Am Med Assoc (1953) 152(12):1090-1093.
5. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med (1998) 338(23):1650-1656. •• Relationship between classical risk factors for CVD, such as hypercholesterolemia and smoking, and the severity of asymptomatic coronary and aortic atherosclerosis in children and young adults was demonstrated.
6. Steinberg D: Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res (2004) 45(9):1583-1593.
7. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Br Med J (2003) 326(7404):1423- 1429.
8. Daniels SR, Greer FR: Lipid screening and cardiovascular health in childhood. Pediatrics (2008) 122(1):198-208. •• These recently released guidelines by the AAP provide opinions and recommendations regarding lipid screening and cardiovascular health management, including pharmacotherapy, in children.
9. De Ferranti FS, Ludwig DS: Storm over statins - The controversy surrounding pharmacologic treatment of children. N Engl J Med (2008) 359(13):1309-1312.
10. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med (1999) 340(2):115-126.
11. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV: Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med (1996) 334(14):884-890.
12. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J: Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation (2006) 114(24):2710-2738. • Describes and categorizes pediatric diagnoses with increased risk for atherosclerosis, such as FH, Kawasaki disease and chronic inflammatory disease.
13. Horiguchi Y, Yamamoto A, Kamiya T, Arakaki Y, Yazawa K, Fujita T: Cardiovascular findings in familial hypercholesterolemic children. Jpn Circ J (1991) 55(2):142-148.
14. Marks D, Thorogood M, Neil HA, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis (2003) 168(1):1-14.
15. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol (2002) 40(12):2117- 2121.
16. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ: Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet (2004) 363(9406):369-370. • It was demonstrated that children with FH have an increased carotid IMT as measured by ultrasonography when compared with healthy siblings.
17. Duivenvoorden R, Nederveen AJ, de Groot E, Kastelein JJ: Atherosclerosis imaging as a benchmark in the development of novel cardiovascular drugs. Curr Opin Lipidol (2007) 18(6):613-621.
18. Baker JL, Olsen LW, Sorensen TI: Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med (2007) 357(23):2329-2337.
19. Lusis AJ, Pajukanta P: A treasure trove for lipoprotein biology. Nat Genet (2008) 40(2):129-130.
20. Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res (1992) 33(11):1569-1582.
21. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366(9493):1267-1278.
22. Avis HJ, Hutten BA, Wijburg FA, Kastelein JJ, Vissers MN: Statin safety in children at increased risk for cardiovascular disease. Arch Med Sci (2008) 3(4A):S147-S157.
23. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA: A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2007) 27(8):1803-1810.
24. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, Sijbrands EJ, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. J Am Med Assoc (2004) 292(3):331-337. •• Statin therapy in children with FH hinders carotid IMT progression.
25. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA: Statin treatment in children with familial hypercholesterolemia: The younger, the better. Circulation (2007) 116(6):664-668. •• The age of the initiation of statin treatment in children with FH is a significant predictor for carotid IMT after a median follow-up period of 4.5 years.
26. Jose J, Saravu K, Shastry BA: Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome. Am J Health Syst Pharm (2007) 64(7):726-729.
27. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR: Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation (2007) 115(14):1948-1967. • An extensive overview of evidence on lipid-lowering drugs for children at an increased risk for developing CVD.
28. Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M: Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther (2003) 74(2):178-185.
29. Wiersma HE, Wiegman A, Koopmans RP, Bakker HD, Kastelein JJ, van Boxtel CJ: Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolemia. Clin Drug Invest (2004) 24(2):113-120.
30. Assessment of the paediatric needs: Cardiovascular products. European Medicines Agency, London, UK (2006). www.emea.europa.eu/pdfs/human/ paediatrics/43964906en.pdf
31. de Jongh S, Kerckhoffs MC, Grootenhuis MA, Bakker HD, Heymans HS, Last BF: Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr (2003) 92(9):1096-1101.
32. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, Veltri E, Avis HJ, Kastelein JJ: Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol (2008) 52(17):1421-1429.
33. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D et al: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 358(14):1431-1443.
34. NCT00202878: IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin (study P04103AM3). Schering-Plough Corp, Kenilworth, NJ, USA (2009). www.clinicaltrials. gov/ct2/show/NCT00202878
35. No authors listed: National Cholesterol Education Program (NCEP): Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics (1992) 89(3):495-501.
36. Daiichi Sankyo Co Ltd: Colesevelam HCl lowered LDL cholesterol in pediatric patients with heterozygous familial hypercholesterolemia. Press Release (2008): November 11.
37. Wheeler KA, West RJ, Lloyd JK, Barley J: Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child (1985) 60(1):34-37.
38. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet (2005) 366(9500):1849-1861.
39. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW: Niacin treatment of hypercholesterolemia in children. Pediatrics (1993) 92(1):78-82.
40. McCrindle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J Pediatr (2003) 143(1):74-80.
41. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO: Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics (2005) 116(3):682-688.
42. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M et al: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation (2002) 106(17):2231-2237.
43. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenmeijer BE, van den Ende A, Büller HR, Bakker HD: Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res (1996) 39(5):867-871.
44. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F et al: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. J Am Med Assoc (1999) 281(2):137-144.